Mitogenic signals initiated at the plasma membrane are transmitted to the nucleus through an intricate signalling network. We identi®ed the protooncoprotein Cot as a new component of mitogenic signalling cascades, which activates both the classic cytoplasmic cascade and the SAPK stress pathway. Wildtype and activated Cot phosphorylate and activate MEK-1 and SEK-1 in vitro. These ®ndings are consistent with the sequence homology between Cot and the rat gene Tpl-2. Expression of oncogenic Cot in 293, NIH3T3 and PC12 cells leads to in vivo phosphorylation of endogenous c-Jun and Erk-1/2 suggesting that the serine/threonine kinase Cot functions beside c-Raf-1 and Mos as a direct activator of MEK-1. Furthermore, we have examined the biological eects of Cot on the phenotype of ®broblastic and neuronal cells. In order to test a potential c-Raf-1 dependency of Cot transformation, the eect of oncogenic Cot on Raf revertant CHP25 cells was determined. Cot could restore the transformed phenotype indicating that Cot transformation is not dependent on active c-Raf-1 and that Cot is not a target for the putative Raf inhibitor, which is presumably active in the revertant cell line. Expression of oncogenic versions of Raf as well as v-Mos leads to dierentiation of PC12 cells. Cot also induces neurite outgrowth of PC12 cells. These data are consistent with the role of Cot in the classic mitogenic cascade and suggest that the simultaneously activated JNK/SAPK stress pathway has no antagonistic eects in this context.
Introduction
Activation of growth factor receptors stimulates a variety of parallel signal transduction cascades (reviewed in Daum et al., 1994; Slupsky et al., 1998) . The best understood signalling pathway is the classic cytoplasmic cascade, which regulates cell proliferation and dierentiation and leads to activation of ERK-1 and ERK-2 (Rapp, 1991; Blenis, 1993; Daum et al., 1994; Slupsky et al., 1998) . Mammalian ERKs are activated by phosphorylation on a threonine and a tyrosine residue in a conserved TEY motif by the dual speci®city protein kinases MEK-1 and MEK-2 (Crews and Erikson, 1992; Cano and Mahadevan, 1995) . These kinases are activated in turn through phosphorylation by the serine/threonine kinase c-Raf-1 (Daum et al., 1994) . The activation of c-Raf-1 following growth factor receptor stimulation typically involves translocation to the plasma membrane, which is mediated by association of c-Raf-1 with GTP bound Ras Daum et al., 1994) .
A second well characterized mammalian protein kinase cascade which is activated after stress such as heat shock, UV-irradiation, osmotic stress or certain cytokines and activation of G protein coupled receptors leads to the activation of JNK/SAPK (Hibi et al., 1993; Kyriakis et al., 1994; Woodgett et al., 1996) . JNK/SAPK is phosphorylated and activated by the dual speci®city kinase SEK/MKK4 (Davis, 1994; Robinson and Cobb, 1997) . Recently, a third mammalian MAPK has been cloned: p38 or RK. p38 is phosphorylated and activated by MKK3, MKK6 and in overexpression experiments also by MKK4 (Davis, 1994; Han et al., 1994; Robinson and Cobb, 1997) .
The serine/threonine kinase Cot was originally cloned from embryonic SHOK cells transformed with DNA extracted from a human thyroid carcinoma cell line (Miyoshi et al., 1991) . The cot gene has suered a gene rearrangement within the last coding exon of the cot proto-oncogene during this procedure (Miyoshi et al., 1991) . The ®rst 397 amino acids of the Cot protein are identical to the oncogenic Cot (CotDC), whereas the 70 carboxyterminal amino acids are replaced by 17 completely dierent ones (Aoki et al., 1993) . Cotransfection experiments with the oncogenic cot and HA-ERK-1 in 293 cells showed activation of ERK-1, which was sensitive to inhibition by the dominant negative cRaf-1 mutant C4 . Further experiments revealed that transformation of NIH3T3 cells by v-cot resulted in a hyperphosphorylated, shifted form of c-Raf-1, which is typical for the active kinase. These results suggested functional interaction between Cot and c-Raf-1 .
Cot and Tpl-2 are highly related at the amino acid level (Miyoshi et al., 1991) . Tpl-2 was originally identi®ed as the product of an oncogene involved in the progression of Moloney murine leukemia virusinduced T-cell lymphomas in rats . Tpl-2 is an intergration locus of the provirus, which leads to expression of a truncated mRNA and an activated kinase, that is altered at the C-terminus . Overexpression of Tpl-2 induces ERK activation in COS-1 and NIH3T3 cells and this activation may depend on the cooperative action of Tpl-2, Ras and c-Raf-1 in a multimolecular complex that leads to the phosphorylation of MEK-1 (Patriotis et al., 1994) . Recently it has been reported that Tpl-2 can phosphorylate and activate MEK-1 and SEK-1 in COS-1 and Jurkat cells independent of Ras and c-Raf-1 (SalmeroÂ n et al,. 1996) .
In this study we have examined the biochemical and biological function of Cot in terms of eects on protein kinase cascades that regulate growth as well as the phenotype of ®broblastic and neuronal cells. Specifically, we show that Cot is involved in the classic cytoplasmic cascade and the SAPK stress pathway. It phosphorylates and activates both MEK-1 and SEK-1, and induces by this ERK and SAPK activation, in vitro and in vivo. These properties are consistent with the sequence homology between cot and the rat gene tpl-2, suggesting that these kinases are encoded by cognate genes. Overexpression of oncogenic Raf or Mos, which are also known to activate MEK, leads to differentiation of PC12 pheochromocytoma cells dependent on ERK activation (Xia et al., 1995; Wixler et al., 1996) . We examined whether the oncogenic version of cot was able to induce neuronal dierentiation of PC12 cells. Indeed, this constitutively active MEK activator Cot leads to neurite outgrowth. Furthermore we showed that Cot could restore the transformed phenotype of Raf revertant cells (Kolch et al., 1993) indicating independence from the active c-Raf-1 kinase.
Results

Cot stimulates ERK via phosphorylation and activation of MEK
To analyse the eect of Cot on the activation of ERK, 293 cells were transfected with wildtype, oncogenic, or a kinase dead form of cot alone or in combination with HA-tagged ERK-1-DNA (Figure 1a ). Forty-eight hours after transfection the cells were lysed and ERK-1 was immunoprecipitated and assayed for its ability to phosphorylate MBP. Coexpression of ERK-1 with c-Raf-BXB, an activated form of c-Raf-1 (Bruder et al., 1992) , was used as a positive control. In agreement with our previously published data we showed that oncogenic Cot activates ERK-1. Additionally we demonstrated that overexpression of wildtype Cot also activated ERK-1, whereas a kinase inactive mutant of Cot failed to do so.
To test at which level of the classic cytoplasmic cascade Cot functions, Sf9 cells were infected with the baculovirus expression constructs for wildtype or oncogenic forms of Cot alone or in combination with recombinant MEK-1 viruses (Figure 1b) . Forty-eight hours after infection, MEK-1 was immunoprecipitated and its kinase activity was assayed using GST ± ERK-1 as a substrate. Expression of either the wildtype or the oncogenic form of Cot resulted in strong activation of MEK-1. No dierence between both forms of Cot was seen when the protein concentrations were taken into consideration. This could be due to the rate limiting amount of immunoprecipitated MEK-1. To test directly whether the in vitro phosphorylation of MEK-1 by Cot resulted in its activation a coupled assay was used. Cot immunoprecipitates (Figure 1d ) were assayed for their ability to phosphorylate and activate wildtype GST ± MEK-1 by including ERK-1 as substrate in the kinase reaction. As shown in Figure  1d , MEK-1 was activated after incubation with immunoprecipitated wildtype or oncogenic Cot as well as with immunoprecipitated active c-Raf-1 which was used as a positive control. The oncogenic form of Cot had a 4.5-fold higher kinase activity compared to the wildtype form.
Both ERK and SAPK can phosphorylate and thus modulate the activity of transcription factors. Reporter gene assays were thus used to further analyse Cot mediated signalling pathways. The reporter construct pB4x (Bruder et al., 1992) contains four copies of the oncogene responsive element from the polyomavirus enhancer inserted upstream of the minimal b-globin promoter fused to the luciferase (luc) gene. It is known that expression of activated Raf stimulates this promoter, which contains Ap-1-and Ets-binding sites in NIH3T3 cells (Bruder et al., 1992) . Transfection experiments in 293 cells revealed that oncogenic as well as wildtype Cot were very strong activators of this promoter (Figure 4a ). The measured luciferase activity was twofold higher than the activity induced by an equal amount of c-Raf-1-BXB DNA. To analyse whether this Cot mediated promoter activation is dependent on the ERK pathway, 293 cells were transfected with a dominant negative mutant of ERK (ERKB3 K52/R52) (Robbins et al., 1993) in combination with Cot and the reporter-construct. The mutant was able to inhibit the Cot mediated promoter activation by 80% suggesting that the ERK pathway was required for the Cot mediated activation of the Ap-1-and Etsdriven promoter (Figure 4a ).
Cot stimulates SAPK via SEK phosphorylation but has no eect on p38
To examine the involvement of Cot in other signal transduction pathways, 293 cells were co-transfected with plasmids encoding Cot and HA-tagged SAPKb (Figure 2a, left panel) . Forty-eight hours after transfection, SAPKb was immunoprecipitated and tested for its ability to phosphorylate GST-c-Jun fusion protein. Expression of either the wildtype or the oncogenic form of Cot resulted in a strong activation of SAPKb.
In order to test at which level of the cascade Cot triggers the activation of SAPK, 293 cells were transfected with the wildtype or the oncogenic form of Cot together with SAPKb and a kinase-inactive mutant of SEK (Sanchez et al., 1994; Ludwig et al., 1996) . As demonstrated in Figure 2a (right panel) an excess of dominant negative SEK was able to block the Cot-induced SAPK activation suggesting a function of Cot upstream or at the level of SEK.
To test whether Cot can directly phosphorylate SEK, immunoprecipitated oncogenic Cot was tested for its ability to phosphorylate kinase inactive GST-SEK K167R in vitro. As shown in Figure 2b , SEK was a direct substrate for Cot whereas no SEK phosphorylation was seen with immunoprecipitates of activated Raf-1 (data not shown).
To analyse whether the SAPK pathway is involved in the Cot mediated Ap-1 and Ets driven promoter activation, 293 cells were transfected with a dominant Figure 1 Cot stimulates ERK via activation of MEK-1 by direct phosphorylation. Lysates were prepared from 293 cells 48 h after transfection with dierent cot constructs alone or in combination with ERK-1 (a). ERK-1 was immunoprecipitated from cell lysates and assayed for its ability to phosphorylate MBP in vitro. Overexpression of CotDC and Cotwt but not of the kinase dead mutant of CotDC led to ERK-1 activation (upper panel). Coexpression of c-Raf-BxB was used as a positive control. Western blot analysis con®rmed the expression of the transfected genes. The expression of Cot in the cotransfection experiment together with ERK was low and only seen in a longer exposure resulting in the appearance of an unspeci®c 60 kDa which runs slightly below wildtype Cot. To observe the MEK-1 dependency of Cot induced ERK-1 activation Sf9 cells were infected with recombinant baculoviruses containing wildtype or oncogenic cot alone or in combination with recombinant MEK-1-viruses (b). MEK-1 was immunoprecipitated from cell lysates and assayed for its ability to phosphorylate kinase dead GST-ERK-1 in vitro. negative mutant of SEK (K167R) (Sanchez et al., 1994; Ludwig et al., 1996) together with Cot and the reporter-construct. The mutant was able to inhibit the Cot mediated promoter activation by 80% suggesting that the SAPK pathway was required as well for the Cot mediated activation of the Ap-1-and Ets-driven promoter ( Figure 4a ). A second protein kinase cascade activated by stress stimuli leads to activation of p38 kinase, another member of the MAPK family (Davis, 1994; Robinson and Cobb, 1997) . In order to test whether p38 is activated by Cot, 293 cells were cotransfected with Cot and p38 (Figure 2c ). Forty-eight hours after transfection p38 was immunoprecipitated and assayed for its ability to phosphorylate 3pK, a known substrate of p38 in vitro (Ludwig et al., 1996) . p38 transfected cells stimulated with anisomycin were used as a positive control. As shown in Figure 2c Cot did not activate 
Cot induces ERK1/2 and c-Jun phosphorylation in 293 cells
The ability of cot to stimulate MAPK in vivo was tested by transfection of 293 cells with oncogenic Cot or stimulation with either TPA or anisomycin ( Figure  3 ). Forty-eight hours after transfection phosphorylated ERK and c-Jun were detected in the lysates using a phospho-ERK1/2 or phospho-c-Jun speci®c antibody. Overexpression of oncogenic Cot induces in 293 cells phosphorylation of endogenous ERK1/2 as well as of c-Jun.
Cot reverts CHP25 cells
The truncated Cot has been shown to have transforming activity in hamster SHOK cells as well as in NIH3T3 ®broblasts (Miyoshi et al., 1991) . Our data indicated that Cot is a MEK activator and functions in the classic cytoplasmic cascade on the same level as cRaf-1. We have previously reported that Cot induced ERK-1 activation was sensitive to inhibition by a dominant negative c-Raf-1 mutant . To test the c-Raf-1 dependency of the transforming potential of oncogenic Cot we examined the sensitivity of CHP25 cells to transformation by Cot. CHP25 is a revertant cell line derived from v-raf transformed NIH3T3 ®broblasts, which express a functional v-raf gene, but fail to form colonies in soft agar and are non tumorigenic (Kolch et al., 1993) . As shown in Figure 5 infection of CHP25 cells with the constitutively active form of Cot enabled them to grow in soft agar. The block in CHP25 cells was not extended to Cot. This data demonstrate that Cot worked independently of an active c-Raf-1 kinase or was not eected by an Raf-speci®c inhibitor which may be active in the revertant cell line. Reporter-gene assays were used to further explore the relationship between cRaf-1 and Cot (Figure 4b ). For these assays a Cterminally truncated form of oncogenic cot (CotDCD) without the oncogene speci®c sequence was used to exclude an in¯uence of this part of the gene. This deletion mutant showed a 30% higher luciferase activity in comparison to CotDC, indicating that the C-terminus may be involved in negative regulation of the kinase. As shown in Figure 4b a dominant negative mutant of Cot could substantially block the c-Raf-1-BXB mediated promoter activation. The dominant negative mutant cRaf-C4B (Bruder et al., 1992) , which interferes with Ras-dependent activation of c-Raf-1, reduced the CotDCD induced promoter activation about 90%. These ®ndings con®rmed the model of a cooperative action of the two MEK activators but stood in contrast to the transformation assay in CHP25 cells. Furthermore this data raised the possibility that regulators of Raf might aect Cot activity.
Cot induces dierentiation of PC12 cells
PC12 pheochromocytoma cells have been used as a model system for dierentiation of neuronal cells.
Observations in PC12 cells gave evidence that the dynamic balance between ERK-and SAPK/p38 pathways is important in determining whether a cell survives or undergoes apoptosis (Xia et al., 1995) . After stimulation with NGF, which activates the classic cytoplasmic cascade, the cells stop growing and start to dierentiate. NGF withdrawal led to sustained activation of the SAPK and p38 kinases and inhibition of ERKs (Xia et al., 1995) . Our data showed that Cot activates both the classic cascade as well as the SAPK pathway. 
Discussion
A rapidly increasing number of kinases were found to be involved in activation of MAPK cascades, as reported recently (Robinson and Cobb, 1997) . The ®rst known MEK activator was c-Raf-1, which is not known to activate MEKs other than MEK1/2 (Rapp et al., 1983a (Rapp et al., ,b, 1988a Slupsky et al., 1998 , 1997) . In this study we present data that demonstrate that the human serine/threonine kinase Cot similarly to the rodent Tpl-2, activates two dierent signal transduction cascades namely the classic cytoplasmic cascade, leading to the activation of ERK, and the stress induced pathway, leading to the activation of JNK/SAPK. Speci®cally, Cot phosphorylates and activates both MEK-1 and SEK-1 in vitro and induces ERK and c-Jun phosphorylation in vivo.
However, expression of Cot shows no eect on the activation of the second stress induced kinase cascade, the p38 pathway. Consistent with the eects on ERK and SAPK Cot was shown to activate the Ap-1-and Ets-driven promoter. Reporter-gene assays revealed an interdependence between Cot and c-Raf-1. A negative regulator of c-Raf-1 that is presumably active in CHP25 Raf revertant cells has no eect on Cot. In contrast to v-mos, this oncogene transformed CHP25 revertant cells. Furthermore we showed that oncogenic Cot had the ability to induce dierentiation of PC12 cells.
Most onco-protein kinases are activators of the RasRaf-MEK-ERK cascade (Heidecker et al., 1989; Rapp et al., 1988a Rapp et al., , 1994 . The unrelated kinases c-Raf-1 and Mos for example phosphorylate and activate MEK and this MEK activation is required for cell transformation and dierentiation Rapp et al., 1994; Wixler et al., 1996) . Under overexpression conditions MEKK-1, which functions in the stress kinase pathway, is able to activate ERK-1. However, this kinase cannot transform cells and indeed activation of the SAPK pathway by MEKK-1 inhibits growth of NIH3T3 cells (Minden et al., 1994; Yan et al., 1994) . The ERK and SAPK pathway therefore appear to mediate opposite eects on cell growth when activated separately. Furthermore, the stimuli that trigger ERK and SAPK generally are discrete suggesting that these pathways are independent (Cano and Mahadevan, 1995) . Our results clearly show that under overexpression conditions Cot triggers both pathways by phosphorylation and activation of MEK and SEK in vitro (Figures 1a and 2c) . We extended these data by the use of phospho-speci®c antibodies in vivo (Figures 3 and 7) . The Cot induced activation of immunoprecipitated SAPK could be due to an autocrine loop triggered by Cot. Expression of an estradiol-dependent form of the c-Raf-1 kinase in NIH3T3 cells results in constitutive activation of the ERK-and the JNK-pathway, but JNK activation is not observed until 16 ± 24 h after c-Raf-1 activation and is independent of de novo protein synthesis (McCarthy et al., 1995; Minden et al., 1994) . This delayed JNK activation is thought to be mediated by a 71 ) were used. Forty-eight hours after infection the cells were lysed and analysed for the presence of phosphorylated ERK1/2 or c-Jun. The expression of endogenous ERK and c-Jun was con®rmed by Western blot analysis. In the case of NIH3T3 cells stable transfectants expressing the same retroviral Cot construct were used. For PC12 cells the eciency of virus transfer was determined 120 h after infection by monitoring neurite outgrowth. 90% of the Cot and 60% of the EHneo infected PC12 cells were dierentiated. In the case of NIH3T3 cells complete morphological transformation was used as an indicator for the presence of activated Cot c-Raf-1 induced autocrine loop involving HB-EGF expression, rather than crosstalk between the pathways (Kerkho and McCarthy et al., 1995) . An overexpression artefact of the Cot induced stimulation of the two kinase cascades cannot be excluded. A temporal dissociation between Cot induced ERK and JNK activation will be further investigated. It is possible that upstream regulators of Cot signalling in¯uence the phosphorylation of the Cot substrates and thereby determine whether the classic cytoplasmic cascade or the JNK pathway is activated.
Because of the high similarity between the amino acid sequence of Cot and Tpl-2 (Miyoshi et al., 1991) and our previous observation of Cot induced ERK-1 activation in 293 cells transiently transfected with Cot , it was proposed that Cot may be the human homologue of the rodent protein (SalmeroÂ n et al., 1996; Patriotis et al., 1993) . Our results support the notion that Cot and Tpl-2 are cognate genes. SalmeroÂ n et al. (1996) recently reported that Tpl-2 phosphorylates MEK-1 and SEK-1 in vitro. Patriotis et al. (1994) reported that Tpl-2 acts in concert with Ras and c-Raf-1 to activate ERK. Contrary to this, the data of SalmeroÂ n et al. (1996) indicate that activation of ERK by Tpl-2 was independent of both Ras and c-Raf-1. Our data support the results of Troppmair et al. (1994) and Patriotis et al. (1994) . The c-Raf-1 kinase is a key protein at the entry-point into the classic cascade and its activation involves multiple interactions of proteins in a large complex (Daum et al., 1994; Morrison and Cutler, 1997; Rapp et al., 1994) . Cot and c-Raf-1 are interdependent as shown in reporter-gene assays. A dominant negative c-Raf-1-mutant (C4B) can partially block the Cot induced promoter activity and a dominant negative Cot mutant reduces the c-Raf-1-BxB induced promoter activity (Figure 4b ). These ®ndings raised the possibility that regulators of c-Raf-1 might aect Cot activity. Raf-1-C4B interferes with Ras-dependent activation of c-Raf-1 suggesting that Ras in¯uences Cot activity as well. Sf9 cells do not express endogenous Ras. Experiments in these cells revealed that Cot is active in the absence of Ras (Figure 1) , whereas c-Raf-1 requires coexpression of Ras and a PTK oncogene for full activation (Cai et al., 1997) . We have suggestive evidence from experiments that Ras has a negative in¯uence on the Cot kinase activity (data not shown). Experiments in CHP25 cells give further evidence for dierential regulation of Cot and Raf as the putative negative regulator of c-Raf-1 does not aect Cot. This Raf revertant cell line is resistant to transformation by most oncogenes such as ras or src which function upstream of c-Raf-1 but were easily transformed by oncogenic versions of proteins out of the Raf eector pathway such as v-fos (Kolch et al., 1993) . The revertant phenotype of CHP25 cells is proposed to result from mutation of a single gene critical for Raf transformation, for example the loss of function of a downstream target of Raf-kinase as opposed to the activation of a transdominant suppressor gene (Kolch et al., 1993) . Because the cells can be retransformed by v-cot ( Figure 5 ) we favour the latter mechanism. As Cot diers from v-Mos, another MEK activator, in its ability to retransform CHP25 cells it seems likely that JNK activation by Cot contributes to transformation of these cells.
These observations lead to the model that c-Raf-1 and Cot may be regulated by the same proteins but in a dierent way. Ras is important for the c-Raf-1 activation, but may have suppressor function in Cot signalling. The suppressor activity in CHP25 cells seems to be restricted to c-Raf-1 and v-Mos and do not aect Cot transforming activity negatively. We will further analyse whether Cot can compensate Raf function and whether these gene products are redundant in the organism.
Since Cot is an oncogene and shows transforming activity in NIH3T3 as well as in hamster SHOK cells (Miyoshi et al., 1991; Aoki et al., 1993) the question arose whether the SAPK/JNK stress cascade, that has been associated with induction of apoptosis, contributed to or opposed the oncogenic activity. In stably transfected NIH3T3-pJJ26 cells both, ERK and c-Jun are phosphorylated whereas the control cells show no phosphorylation ( Figure 7) . As PC12 cells were reported to be sensitive to the apoptosis-inducing function of JNK/SAPK, we examined the eects of Cot in this cell system. We observed that oncogenic Cot also induced neurite outgrowth, indicating the involvement of Cot in the ERK pathway ( Figure 6 ). The phosphorylation of endogenous ERK1/2 was strongly enhanced in Cot infected cells in comparison to control cells. In addition both c-Jun phosphorylation and expression were increased (Figure 7) . These results are consistent with recent data reporting that PC12 cell dierentiation requires the induction of c-Jun synthesis as well as c-Jun phosphorylation. Whereas both ERK and JNK can catalyse phosphorylation of the relevant sites in c-Jun, only the former can stimulate c-Jun expression in PC12 cells eciently (LeppaÈ et al., 1998) . JNK signalling by itself can not induce PC12 cell dierentiation (LeppaÈ et al., 1998) .
Although not suggested by our experiments it could be that the Cot induced activation of the SAPK/JNK pathway is cell type dependent. Further experiments will be required to understand cooperative versus antagonistic function of these pathways.
Materials and methods
Expression constructs
Full length Cotwt cDNA was subcloned into pVL1393 for baculovirus/Sf9 cell expression experiments and into pCMV-5 for 293 cell experiments. The oncogenic cotDC c-DNA encodes a c-terminally truncated form of Cot which terminates at residue 415. An EcoRI fragment of cotDC c-DNA was subcloned from pUC13 into the pVL1393 and pCMV-5. A kinase inactive form of Cot was generated by mutating K167 to R in the cotwt-pCMV-5 construct with the QuikChange TM Site-Directed Mutagenesis Kit (Stratagene) using the sense primer 5'-GGCGTGTAGACT-GATCCC-3' and the corresponding antisense primer. cotDCD, a c-terminal truncated oncogenic form of Cot without oncogene speci®c sequence, was generated with the QuikChange TM Site-Directed Mutagenesis Kit (Stratagene) using the sense primer 5'-GATCAGCCACGCTAGGCCC-CACC-3' and the corresponding antisense primer. The mutations were veri®ed by DNA-sequencing.
Cell lines
CHP25 cells and NIH3T3 cells were maintained as described by Kolch et al. (1993) . Retroviral infections were performed as described previously (Rapp and Todaro, 1978) . PC12 cells were cultured as described (Wixler et al., 1996) . NGF treatment (Gibco) was performed using a ®nal concentration of 50 ng/ml. No starved cells were used. Retroviral infections were carried out as described (Rapp and Todaro, 1978) .
Sf9 insect cells were maintained in IPL-41 insect medium (Gibco) supplemented with 10% heat-inactivated fetal calf serum (PAN), 1% tryptose, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin. The cells were propagated at 278C in a suspension culture. Infections were performed with 10 7 Sf9 cells and 10 MOI of baculoviruses expressing Cotwt, CotDC, CotK167R or MEK-1. The cells were cultured at 278C for 48 h before harvesting.
293 embryonal kidney cells were grown in Dulbecco's modi®ed Eagle's medium (Gibco) supplemented with 10% heat-inactivated fetal calf serum (PAA), 2 mM L-glutamine, 100 U/ml penicillin/streptomycin. The cells were maintained at 378C 5% CO 2 and 90% humidity. Soft agar-cloning was performed as described (Rapp and Todaro, 1978) . Transfections were performed following a modi®cation of the calcium phosphate coprecipitation method (Chen and Okayama, 1987) . Total amount of DNA transfected was kept constant by ®lling up with vector DNA. Six to twelve hours after transfection precipitates were removed by washing with phosphate buered saline (PBS) and cells were refed with medium containing 0.3% serum. Forty-eight hours after transfection cells were washed with PBS and cell pellets were either shock frozen in liquid nitrogen and stored at 7808C or analysed directly.
Antibodies
Immunoprecipitation and Western blotting of Cot and Tpl-2 was carried out using the rabbit antiserum Cot-AS 500 raised against a N-terminally peptide corresponding to aminoacids 5 ± 23 and the goat Tpl-2 antiserum N-17 (Santa Cruz). For Immunoprecipitation and Western blotting the following antibodies were used: c-Raf-1 501, rabbit polyclonal (Rapp lab); MEK-1 (C-18), rabbit polyclonal (Santa Cruz); 12CA5, mouse monoclonal (Field et al., 1988) ; PhosphoPlus TM p44/42 MAPK (Tyr204), rabbit polyclonal (Biolabs); ERK1 (C16) rabbit polyclonal (Santa Cruz); c-Jun (KM-1) mouse monoclonal (Santa Cruz); c-Jun, rabbit polyclonal (Biolabs).
Immunoprecipitation
Forty-eight hours after infection (Sf9 cells) or transfection (293 cells) cells were washed twice with ice-cold PBS and lysed in NP-40 buer (0.2% (v/v) NP-40, 25 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 1 mM Na-orthovanadate, 10 mM Napyrophosphate, 1 mg/ml aprotinin and 1 mg/ml leupeptin) for 15 min at 48C. The lysates were precleared by centrifugation (12 000 g at 48C for 10 min). Nine hundred mg of total cellular protein were incubated with 20 ml of Protein G agarose (Boehringer) and the indicated antibody for Cot or MEK-1 proteins for 2 h at 48C. The immunoprecipitates were washed twice in lysis buer. The immunoprecipitate/agarose complexes were recovered after each wash by a two minute centrifugation at 10 000 g at 48C.
In vitro kinase assay
The immunoprecipitates were washed once in kinase buer (50 mM HEPES, pH 7.5, 50 mM b-glycerophosphate, 3 mM EGTA, 10% (v/v) glycerol, 2 mM DTT, 20 mM MgCl 2 , 200 mM ATP). Samples were resuspended in 30 ml of kinase buer containing 5 mCi [g-32 P]ATP (3000 Ci/mM, Amersham) and 4 mg of recombinant K97M kinase dead MEK mutant protein (MEK-kinase assay), 4 mg of recombinant K167R kinase dead GST-SEK mutant protein or a kinasedead ERK mutant protein and incubated at 308C for 15 min. A coupled assay was performed in the presence of 2 mg GST-MEK and 2 mg of the kinase-dead ERK mutant (Robbins et al., 1993; Alessi et al., 1994) . Samples were resuspended in 30 ml SDS ± PAGE loading buer (60 mM Tris/HCl, pH 6.8, 10% (v/v) glycerol, 3% (w/v) SDS, 5% (v/v) b-mercaptoethanol, 0.005% (w/v) bromphenol blue). Following size fractionation in 10% SDS ± PAGE gels, proteins were transferred to a nitrocellulose membrane using a tank blot procedure (Bio-Rad Mini-PROTEAN II) in a buer containing 25 mM Tris and 190 mM Glycine. The blot was performed at 400 mA for 1 h. Quanti®cation of kinase activity was done using the Bio Imaging Analyser BAS 2000 (Fuji).
Immunoblotting
Proteins were separated as described above. The membrane was blocked over night at 48C in PBS buer supplemented with 5% (w/v) nonfat dried milk and 0.05% (v/v) Tween 20 and incubated on a platform shaker at room temperature for 3 h with appropriate dilutions of the antibodies in blocking buer. Afterwards the blot was washed three times for ten minutes with PBS buer supplemented with 0.05% Tween 20 and incubated on a platform shaker at room temperature for 1 h in PBS buer supplemented with 1.6% (w/v) nonfat dried milk and a 1:3000 dilution of Protein A horseradish peroxidase-coupled secondary antibody. The blot was washed three times for 10 min with PBS buer supplemented with 0.05% Tween 20 and the protein bands were visualized using the ECL detection system (Amersham).
Luciferase assay
Cell pellets were lysed in 400 ml harvesting buer (50 mM Tris, 50 mM MES, pH 7.8, 1 mM DTT, 0.1% Triton X-100), precleared by centrifugation (15 000 g, 10 min at 48C), standardized for protein concentration and 50 ml of lysate were analysed together with 50 ml of assay buer (125 mM Tris, 125 mM MES, pH 7.8, 25 mM magnesium acetate, 5 mM ATP) and 50 ml of D-luciferin (1 mM in 5 mM KHPO 4 , pH 7.8) in a luminometer (Microlumat LB 96P, Berthold AG, Germany).
Abbreviations
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